New diabetes pill shows promise in Mid-Stage trial

NCT ID NCT07321678

Ongoing Disease control Sponsor: Ascletis Pharma (China) Co., Limited Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 15 times

Summary

This study tests an experimental tablet called ASC30 in 100 adults with type 2 diabetes. The goal is to see if it can lower blood sugar and help with weight over 13 weeks compared to a placebo. Participants must have stable weight and a BMI of 23 or higher. The study is active but no longer recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Ascletis Clinical Site

Riverside, California, 92506, United States
Ascletis Clinical Site

San Jose, California, 95128, United States
Ascletis Clinical Site

Denver, Colorado, 80246, United States
Ascletis Clinical Site

Miami, Florida, 33143, United States
Ascletis Clinical Site

Miami, Florida, 33172, United States
Ascletis Clinical Site

Decatur, Georgia, 30030, United States
Ascletis Clinical Site

Springfield, Missouri, 65802, United States
Ascletis Clinical Site

San Antonio, Texas, 78240, United States

Conditions

Explore the condition pages connected to this study.

T2DM (TYPE 2 DIABETES MELLITUS) T2DM (TYPE 2 DIABETES MELLITUS)